Product/Composition:- | Plasma Protein Fraction (PPF) powder |
---|---|
Strength:- | 50 mL, 250 mL, or 500 mL |
Form:- | Lyophilized Powder or Liquid |
Reference Brands:- | Plasmanate (US), Octaplas LG, Biotest Plasma (EU) |
MOQ | As per the manufacturer batch size |
Get Quote Send Enquiry on WhatsApp |
Plasma Protein Fraction (PPF) provides essential plasma proteins, including albumin and clotting factors, supporting blood volume and coagulation. It restores plasma volume, improves hemodynamic stability, and replaces deficient plasma proteins in various conditions. Benefits include quick plasma protein replenishment, blood volume expansion, and enhanced clotting, supporting critical patient care.
Plasma Protein Fraction (PPF) powder, such as Plasmatate and Octaplas LG, is approved in the US by the FDA and in the EU via EMA for replacing plasma proteins in various clinical conditions. Regulatory approval requires a comprehensive dossier including clinical efficacy, safety data, manufacturing quality, and pharmacovigilance plans. In the US, the FDA reviews detailed clinical and manufacturing information, while the EMA ensures compliance with regional standards. For guidance on dossier preparation, regulatory pathways, and market access, visit PharmaTradz. Ensuring thorough regulatory compliance is essential for the safe, effective, and timely approval of PPF powder products worldwide, supporting optimal patient care.